Atropine therapy has a direct treatment effect on choroidal thickness, which cannot be fully explained by axial length or SER changes.

Contineum Therapeutics, Inc.’s CTNM share price has dipped by 11.19%, which has investors questioning if this is right time to buy.

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

University of California has described tropane derivatives acting as 5-HT2 and muscarinic receptor ligands reported to be useful for the treatment of psychiatric disorders, depression, ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...

导言精神疾病领域的研究在2024年取得了令人瞩目的进展，不仅在创新药物的研发和适应症扩展方面不断突破，也在发病机制和生物学基础等基础研究层面深入拓展，为精神疾病的诊疗与预后带来了新的可能性。特别是在精神分裂症、双相情感障碍以及阿尔茨海默症等重大精神和神经退行性疾病领域，多个新型药物相继获批或推进到后期临 ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...